Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Purpose

The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.

Condition

  • Myocardial Infarction

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

For the first 50 patients at each participating site, consecutive patients are entered in the registry if they are ≥ 18 years of age, underwent coronary angiography for a STEMI or NSTEMI, and received cangrelor at any time during the hospitalization or an oral P2Y12 inhibitor during his/her first 48 hours of the hospitalization for MI. Phase 2 Inclusion Criteria: Subsequent patients are eligible to be entered in the registry if they are ≥ 18 years of age and underwent coronary angiography for a STEMI or NSTEMI and meet at least 1 of the following criteria: 1. The patient was hospitalized for STEMI and met one of the following inclusion criteria: - The patient received cangrelor at any time during his/her hospitalization for MI. - The patient received an oral P2Y12 inhibitor during his/her first 48 hours of hospitalization AND either of the following: - The patient received a P2Y12 inhibitor and an opiate/opioid within 24 hours prior to or during primary PCI for STEMI presentation. OR - The patient underwent coronary angiography followed by CABG during the index MI admission and received any P2Y12 inhibitor within 7 days prior to CABG. 2. The patient was hospitalized for NSTEMI and met one of the following inclusion criteria: - The patient received cangrelor during his/her hospitalization for MI. - The patient received an oral P2Y12 inhibitor during his/her first 48 hours of hospitalization AND either of the following: - The patient underwent coronary angiography followed by CABG during the index MI admission and received any P2Y12 inhibitor within 7 days prior to CABG. OR - Any 2 of the following criteria without prior PCI or CABG: age> 60 years, male sex, diabetes, EF <40% prior heart failure

Exclusion Criteria

If the patient does not meet the inclusion criteria for either Phase.

Study Design

Phase
Study Type
Observational
Observational Model
Case-Only
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
STEMI/NSTEMI Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction

Recruiting Locations

MedStar Health Research Institute, Inc.
Hyattsville, Maryland 20782
Contact:
Syed Ali

More Details

Status
Recruiting
Sponsor
Chiesi USA, Inc.

Study Contact

Leo Brothers
919-668-8322
joseph.l.brothers@duke.edu

Detailed Description

The CAMEO registry is a multicenter observational registry that will collect information on 4,000 patients with NSTEMI or STEMI treated with cangrelor or an oral P2Y12 inhibitor into the registry. Phase 1: Each site will abstract data from the medical record for the first 50 patients meeting the inclusion and exclusion criteria treated at the hospital within 4 months prior to study initiation or during the study period. Phase 2: After Phase 1, all cangrelor-treated patients meeting the inclusion and exclusion criteria treated at the hospital no later than 1 month from the discharge date will be entered into the registry, and we will begin sampling non-cangrelor patients in a 2:1 cangrelor: non-cangrelor ratio.